当前位置: 首页 > 期刊 > 《健康大视野·医学分册》 > 202018
编号:13809324
核苷类抗病毒药物+微生态制剂治疗HBV感染失代偿期肝硬化的有效性评价
http://www.100md.com 2020年9月15日 《健康大视野》 202018
     【摘 要】目的:分析核苷类抗病毒药物+微生态制剂治疗HBV感染失代偿期肝硬化的有效性。方法:将我院接收的70例HBV感染失代偿期肝硬化患者,随机分为两组后,对照组采取常规治疗联合核苷类抗病毒药物治疗,分析组在对照组的基础上加用微生态制剂治疗,就两组患者的治疗效果进行对比。结果:分析组患者治疗总有效率较之对照组更高且两组患者不良反应发生率相近。结论:对HBV感染失代偿期肝硬化患者应用核苷类抗病毒药物联合微生态制剂治疗可取得很好的疗效,且不良反应较少,此治疗方案值得推广应用。

    【关键词】HBV感染失代偿期肝硬化;核苷类抗病毒药物;微生态制剂

    Abstract:Objective To analyze the effectiveness of nucleoside antiviral drugs + micro-ecological preparations in the treatment of cirrhosis in the decompensated stage of HBV infection. Methods: 70 patients with decompensated HBV infection in our hospital were randomly divided into two groups. The control group was treated with conventional therapy combined with nucleoside antiviral drugs. The analysis group was added with microecology on the basis of the control group Preparation treatment ......

您现在查看是摘要页,全文长 5135 字符